NHL Cyberfamily

Non-Hodgkin's lymphoma support

 

DLBC relapse treatment options

When a stem cell transplant is not an option



 

Relapsed DLBC treatment options

As a general rule patients who have diffuse large B-cell lymphoma who relapse after initial treatment will be offered an autologous stem cell transplant as the preferred treatment.  However not every patient is able, or willing to undergo a stem cell transplant.

There is no single treatment alternative to SCT that is universally accepted as the "best" option for everyone. Therefore on this page we will try to give you a list of treatment options that are being used for relapsed DLBC, and other aggressive forms of NHL. Please be sure to discuss them with your doctor if you find yourself in this situation.

  1. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

  2. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

  3. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  4. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an Effective Regimen in Relapsed Diffuse Large B-cell Lymphoma.

  5. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

  6. Efficacy, safety, and cost efficiency of rituximab, gemcitabine, dexamethasone, and oxaliplatin (RGDOx) in B-cell NHL

  7. Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma.

  8. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma

  9. A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

  10. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

  11. Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results

  12. Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell–like than in germinal center b-cell–like phenotype

  13. Phase II Trial Shows Zevalin(R) Effective Therapy for Relapsed/Refractory Patients With Diffuse Large B-Cell Lymphoma

  14. A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results

  15. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

  16. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.


website
statistics